Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors

International Journal of STD and AIDS

Volumn 23, Issue 7, 2012, Pages 459-463

  Bucciardini, R ^a   D'Ettorre, G ^b   Baroncelli, S ^a   Ceccarelli, G ^b   Parruti, G ^c   Weimer, L E ^a   Fragola, V ^a   Galluzzo, C M ^a   Pirillo, M F ^a   Lucattini, S ^a   Bellagamba, R ^d   Francisci, D ^e   Ladisa, N ^f   Degli Antoni, A ^g   Guaraldi, G ^h   Manconi, P E ⁱ   Vullo, V ^b   Preziosi, R ^j   Cirioni, O ^k   Verucchi, G ^l   Floridia, Marco ^a   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SPIRITO SANTO HOSPITAL   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY HOSPITAL OF PARMA   (Italy)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

ⁱ UNIVERSITY OF CAGLIARI   (Italy)

^j Belcolle Hospital   (United States)

^k UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^l UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Antiretroviral therapy; HIV; Raltegravir; Salvage regimen; Virological failure

Indexed keywords

ATAZANAVIR; DARUNAVIR; ENFUVIRTIDE; ETRAVIRINE; MARAVIROC; RALTEGRAVIR; VIRUS RNA;

ADULT; AGE; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMOSENSITIVITY; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; FEMALE; FOLLOW UP; GENDER; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RNA, VIRAL; SALVAGE THERAPY; VIRAL LOAD;

EID: 84864430333     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2012.011391     Document Type: Article

References (12)

1. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54
2. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010;50:605-12
3. Gatell JM, Katlama C, Grinsztejn B, et al. for the Protocol 005 Team. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 2010;53:456-63
4. Young J, Scherrer A, Günthard H, et al. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Med 2011;12:299-307
5. Santos JR, Llibre JM, Domingo P, et al. High effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients. AIDS Res Hum Retroviruses 2011;27:713-7
6. Soriano V, Perno CF, Kaiser R, et al. When and how to use maraviroc in HIV-infected patients. AIDS 2009;23:2377-85
7. Bucciardini R, Murri R, Guarinieri M, et al. ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era. Qual Life Res 2006;3:377-90
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2011;1-166. See http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf (last checked 28 December 2011)
9. Tozzi V, Zaccarelli M, Bonfigli S, et al. Collaborative Group for Clinical Use of HIV Genotype Resistance Test. Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome. Antivir Ther 2006;11:553-60
10. Torti C, Quiros-Roldan E, Regazzi M, et al. RADAR-MASTER Study Group. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis 2005;40:1828-36
11. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359: 355-65
12. Bansi L, Smith C, Phillips A, Kirk S, Geretti AM, et al. on behalf of the UK Collaborative HIV Cohort (CHIC) Study and the UK Collaborative Group on HIV Drug Resistance (HDRD). The impact of HIV drug resistance testing on changes to treatment. AIDS 2011;25:603-10